<DOC>
	<DOCNO>NCT00695617</DOCNO>
	<brief_summary>The optimal anticoagulation procedure MARS treatment define . In various multi-centre trial , MARS-RELIEF , anticoagulation procedure leave discretion treat physician . On one hand , give increase risk bleeding associate liver failure , high dosage anticoagulation therapy avoid . On hand , contact blood blood component extracorporeal circuit likely result coagulation activation even loss coagulation factor . Citrate anticoagulation gain popularity , especially hemodialysis patient . It result highly effective anticoagulation , exclusively confine extracorporeal circulation . Moreover , dependent type dialyser membrane , citrate anticoagulation result reduced activation cellular component . In contrast hemodialysis patient , experience citrate anticoagulation treatment artificial liver device limit . The liver contribute substantially metabolism exogenous citrate . As result , cirrhotic patient decrease endogenous citrate clearance . Importantly , blood purification device contribute substantially overall citrate clearance , thereby prevent accumulation citrate . Several centre , include , gain experience citrate anticoagulation fractionate plasma separation adsorption ( FPSA ) , relate liver dialysis device , treatment liver failure patient . Citrate anticoagulation MARS treatment study far .</brief_summary>
	<brief_title>Citrate Anticoagulation During MARS Treatment</brief_title>
	<detailed_description />
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Scheduled MARS treatment Age 18 year Informed consent Admitted Intensive Care Unit Blood plasma transfusion within 48 hour study Hypocalcemia ( ionise Ca &lt; 0.90 mmol/l ) Acidosis ( pH &lt; 7.25 ) due cause Use citrate containing medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>MARS treatment</keyword>
	<keyword>Citrate anticoagulation</keyword>
</DOC>